ImmunoCellular Therapeutics Announces Asset Purchase Agreement with Private Biotechnology Company
Al Musella's Comments: (This is his personal views and are not necessarily the views of the Musella Foundation!)
This is great news. ICT-107 is an off the shelf vaccine for GBM. The early clinical trials looked very good, but the final clinical trial "failed" and they stopped development of it. However, there were quite a few responses and long term survivors from that trial. There were probably some mistakes made in that trial design. Patients that had certain biomarkers did well enough (adding over a year to median time to progression compared to those without the biomarker) get FDA approval but patients without those biomarkers had no benefit. Hopefully this new company will run the correct trial and make this vaccine available. This is literally a shot in the arm (or leg) with the same side effects profile as the flu shot, and there are a few long term survivors out over 7 years who are not only alive, but in good shape, happy and still working.
Posted on: 07/17/2019
Click HERE to return to brain tumor news headlines